em. prof. dr. Geert Leroux-Roels
- ORCID iD
- 0000-0001-5968-2542
Show
Sort by
-
- Journal Article
- A1
- open access
Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant
-
- Journal Article
- A1
- open access
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial
-
- Journal Article
- A1
- open access
Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin
-
- Journal Article
- A1
- open access
Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine
-
- Journal Article
- A1
- open access
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
-
- Journal Article
- open access
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
-
- Journal Article
- A1
- open access
Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4+ T cell immunity within the FLUCOP consortium
-
- Journal Article
- A1
- open access
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
-
- Journal Article
- A1
- open access
Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium
-
- Journal Article
- A1
- open access
The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
-
- Journal Article
- A1
- open access
Characterization of the cell-mediated immune response to Takeda’s live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting
-
- Journal Article
- A1
- open access
Randomized, double-blind, reference-controlled, phase 2a study evaluating the immunogenicity and safety of OVX836, a nucleoprotein-based influenza vaccine
-
- Journal Article
- A2
- open access
Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine : 4-year follow-up of a phase 1 multicentre trial
-
- Journal Article
- A1
- open access
Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6 (R) cell-line : a phase 1 randomized controlled trial in adults
-
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers : a phase 1 trial
-
- Journal Article
- A1
- open access
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults : two clinical trials
-
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT) : a randomised, double-blind, phase 3 trial
-
- Journal Article
- A1
- open access
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : a phase 1 randomized clinical trial
-
- Journal Article
- A1
- open access
Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine : a phase 3 randomized clinical trial
-
- Journal Article
- A1
- open access
A role for B cells to transmit hepatitis C virus infection
-
- Journal Article
- A1
- open access
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01(B) vaccination
-
- Journal Article
- A1
- open access
Detection of H1 swine influenza a virus antibodies in human serum samples by age group
-
- Journal Article
- A1
- open access
Adjuvant-associated peripheral blood mRNA profiles and kinetics induced by the adjuvanted recombinant protein candidate tuberculosis vaccine M72/AS01 in Bacillus Calmette–Guérin-vaccinated adults
-
- Journal Article
- A1
- open access
Differences in antigenic sites and other functional regions between genotype A and G mumps virus surface proteins
-
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
-
- Journal Article
- A1
- open access
Long-term persistence of cell-mediated and humoral responses to A(H1N1)pdm09 influenza virus vaccines and the role of the AS03 adjuvant system in adults during two randomized controlled trials
-
- Journal Article
- A1
- open access
Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans
-
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo
-
Characterization of a novel monoclonal antibody targeting epitope II within hepatitis C virus E2 envelope glycoprotein
-
Successful engraftment of human hepatocytes in uPA-SCID and FRG® KO mice
(2017) Hepatocyte transplantation : methods and protocols. In Methods in Molecular Biology 1506. p.117-130 -
Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice
-
Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma
-
- Conference Paper
- C3
- open access
Development and characterization of a human monoclonal antibody for prevention of HCV recurrence in liver transplant patients
-
- Conference Paper
- C3
- open access
Impact of HEV infection on the human hepatic innate immune response in human liver chimeric mice
-
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
-
Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants : a comparative, observer-blind, randomised, controlled trial
-
A randomized, observer-blind phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women
-
- Journal Article
- A1
- open access
Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults
-
- Journal Article
- A1
- open access
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine : results from a phase II, randomized, multicenter trial
-
- Journal Article
- A1
- open access
Neutropenia as an adverse event following vaccination : results from randomized clinical trials in healthy adults and systematic review
-
- Journal Article
- A1
- open access
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults : a phase 3, randomized trial and post-hoc correlate of protection analysis
-
- Journal Article
- A1
- open access
Antibody persistence and booster responses to split-virion H5N1 avian influenza vaccine in young and elderly adults
-
- Journal Article
- A1
- open access
A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum
-
- Conference Paper
- C3
- open access
Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice
-
Characterization of a novel human monoclonal antibody targeting the hepatitis C virus envelope protein
-
- Conference Paper
- C3
- open access
A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum
-
Metabolic studies of prostanozol with the uPA-SCID chimeric mouse model and human liver microsomes
-
Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge
-
In vitro and in vivo metabolism studies of dimethazine
-
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice